Daily Stock List
OncBioMune Pharmaceuticals, Inc. (OBMP)
Otcstockexchange, Whisper from Wall Street, Journal Transcript, and MissionIR reported on OncBioMune Pharmaceuticals, Inc. (OBMP), and we also highlight the Company, here at the QualityStocks Daily Newsletter.
OncBioMune Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It engages in the development of novel cancer products and a proprietary vaccine technology. The Company has a proprietary Vaccine Technology designed to stimulate the immune system to attack its own cancer while not hurting the patient. OncBioMune Pharmaceuticals incorporates scientifically proven and clinically validated treatments for cancer. The Company is based in Baton Rouge, Louisiana.
OncBioMune Pharmaceuticals’ lead product is ProscaVax™ - its novel cancer vaccine for prostate cancer. ProscaVax is now undergoing evaluation in a Phase 1 clinical study at the University of California San Diego Moores Cancer Center and Veterans Hospital in La Jolla, California, funded in part by the Department of Defense US Navy Cancer Vaccine Program. OncBioMune also has a portfolio of targeted therapies. Some of these are biosimilars to blockbuster drugs.
The expectation is that a Phase 2/3 trial of ProscaVax will begin enrollment in the near future in Mexico through a Joint Venture (JV) with Vitel Laboratorios, S.A. de C.V. evaluating ProscaVax for the treatment of PSA recurrent prostate cancer in hormone-naïve and hormone-independent patients. In addition, a Phase 2 trial is planned to be initiated at Beth Israel Deaconess Medical Center and partners to evaluate ProscaVax in prostate cancer patients in the "active surveillance" category.
OncBioMune has developed the therapeutic cancer vaccine for prostate cancer patients using similar techniques developed for breast cancer patients. The Company states that it is tested and laboratory proven and that it could become the standard of care for prostate cancer treatment. OncBioMune Pharmaceuticals uses patented technology developed and or acquired by the Company.
Last month, OncBioMune Pharmaceuticals provided the latest clinical data of ProscaVax. In the continuing Phase 1 clinical trial, ProscaVax is undergoing evaluation for safety and efficacy in prostate specific antigen (PSA) recurrent prostate cancer in hormone-naïve and hormone-independent patients. For each protocol, 20 patients are expected to be enrolled in the 1a portion of the study, with therapy comprising six ProscaVax induction vaccinations at a single dose. So far, as of January 26, 2017, 16 prostate cancer patients have enrolled in the trial.
Yesterday, the Company announced that its abstract, illustrating research on its novel therapeutic cancer vaccine, was accepted for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, D.C.
OncBioMune Pharmaceuticals, Inc. (OBMP), closed Friday's trading session at $0.20995, up 6.80%, on 265,321 volume with 95 trades. The average volume for the last 60 days is 86,517 and the stock's 52-week low/high is $0.10/$2.00.
Southern Silver Exploration Corp. (SSVFF)
Streetwise Reports and Real Pennies reported earlier on Southern Silver Exploration Corp. (SSVFF), and we report on the Company today, here at the QualityStocks Daily Newsletter.
Southern Silver Exploration Corp. is a precious metals exploration and development company. It concentrates on the discovery of world-class mineral deposits in north-central Mexico and the southern U.S. The Company’s growth strategy is to focus on the development of quality assets, in significant mineralized trends, close to infrastructure. Southern Silver Exploration has its headquarters in Vancouver, British Columbia.
The Company engages in the acquisition, exploration, and development, either directly or by way of joint-venture (JV) relationships, in mineral properties in major jurisdictions. Southern Silver’s specific emphasis is the Cerro Las Minitas silver-lead-zinc project situated in the heart of Mexico's Faja de Plata.
Southern Silver Exploration is focusing on its exploration efforts in developing the Cerro Las Minitas project into a first-rate, high-grade, silver-lead-zinc mine. The Cerro Las Minitas silver-lead-zinc property is over 130 square kilometers in size. The Cerro Las Minitas property comprises 18 concessions, totaling about 13,640 hectares.
Furthermore, the Company’s property portfolio includes its 100 percent owned Oro porphyry copper-gold project in southern New Mexico. This is its 1,150 hectare, gold, silver, copper, lead and zinc property. Oro features a classic porphyry zonation over a six-square kilometer area within the highly prospective Laramide Porphyry belt of the southern U.S. The Oro Project consists of eight patented mining claims and 89 BLM (Bureau of Land Management) mineral claims.
In October 2016, Southern Silver Exploration reported that funding was approved by Electrum Global Holdings L. P., as Optionee, and final preparations were taking place for a US$2.0 million, 2016-17 exploration program on the Cerro Las Minitas Project, Durango, Mexico. The exploration program consists of 16 holes totaling roughly 10,000 meters of core drilling.
In November, Southern Silver Exploration reported results from Reverse Circulation (RC) drilling on the Stockpond gold target of the Oro project, southwestern New Mexico. Drilling intersected widespread alteration and a thick zone of strongly anomalous gold mineralization in a sediment-hosted oxide-gold system positioned on the edge of the drill pattern, which remains open laterally to the east, north, and south under thin gravel cover.
Last month, Southern Silver Exploration reported assay results from the Fall 2016 core drilling on the Cerro Las Minitas project, Durango State, that identified a thick interval of semi-massive and massive sulphide mineralization in drill hole 16CLM-091. Highlights from 16CLM-091 include a 15.1m down hole interval (14.8m est. True Thickness) averaging 39.4g/t Ag, 0.1% Pb, and 10.2% Zn (410.7g/t AgEq; 11.6% ZnEq). This includes a higher grade 4.8m interval (4.7m est. TT) averaging 38.7g/t Ag, 0.12% Cu, 0.1% Pb, and 23.2% Zn (877g/t AgEq; 24.8% ZnEq).
Southern Silver Exploration Corp. (SSVFF), closed Friday's trading session at $0.365, up 4.05%, on 139,025 volume with 45 trades. The average volume for the last 60 days is 67,624 and the stock's 52-week low/high is $0.0294/$0.516.
Matinas BioPharma Holdings, Inc. (MTNB)
Wall Street Mover, Tiny Gems, SmallCapVoice, Stock News Now, and Stock News reported earlier on Matinas BioPharma Holdings, Inc. (MTNB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company based in Bedminster, New Jersey. It concentrates on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections. The Company’s proprietary, disruptive technology uses lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. Matinas BioPharma Holdings’ shares trade on the OTCQB.
The Company’s emphasis is on the development and commercialization of lipid-based prescription therapeutics for the treatment of infectious diseases and cardiovascular and metabolic conditions. Its focus is on creating highly differentiated, safe, and efficacious therapies using its expertise in drug formulation and development to address important unmet medical needs. More recent additions to its product pipeline, including MAT2203 and MAT2501, position Matinas to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulations.
Matinas BioPharma has its clinical development strategy for MAT2203 (its lead drug candidate currently in Phase 2), a novel lipid-crystal nano-particle orally delivered formulation of Amphotericin B for the treatment of invasive fungal infections, and MAT2501, an early-stage program to treat gram-negative bacterial infections using an orally available formulation of Amikacin, a broad-spectrum aminoglycoside. Matinas has an open Investigational New Drug (IND) application for MAT2501, currently in Phase 1.
In addition, the Company has its investigational drug MAT9001. This is a proprietary prescription-only omega-3 fatty acid-based composition, consisting of docosa-pentaenoic acid (DPA) and other omega-3 fatty acids, which is under development for therapeutic applications with severe hypertriglyceridemia (TG>500 mg/dL) as the lead indication. Matinas has purposely designed MAT9001 to provide a differentiated pharmacotherapy for the treatment of dyslipidemia.
Matinas BioPharma received a Notice of Allowance of U.S. patent for encochleated siRNA, providing a pathway to the development of orally administered RNA based therapies. The Company’s investigational drug MAT2501 (encochleated amikacin) was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of non-tuberculous mycobacteria (NTM) infections, its lead chronic indication.
Recently, Matinas BioPharma announced that it received a research contract award from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) to study its lead antibiotic product candidate MAT2501, for the treatment of pre-clinical nontuberculous mycobacterium infection (NTM) in models of cystic fibrosis (CF). CFFT is the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation.
The award provided by CFFT will support a collaborative research program between Matinas BioPharma and Colorado State University (CSU) to study the efficacy of MAT2501 in the treatment of NTM infection by a range of mycobacterium species, including mycobacterium abscessus, in a CF lung infection model developed by CSU.
In 2017, Matinas BioPharma will open a new GLP/cGMP manufacturing facility, which will position the Company for expected pivotal programs for MAT2203 and MAT2501.
Matinas BioPharma Holdings, Inc. (MTNB), closed Friday's trading session at $2.56, down 1.54%, on 196,059 volume with 231 trades. The average volume for the last 60 days is 87,824 and the stock's 52-week low/high is $0.411/$2.75.
NEMUS Bioscience, Inc. (NMUS)
We are reporting on NEMUS Bioscience, Inc. (NMUS) today, here at the QualityStocks Daily Newsletter.
NEMUS Bioscience, Inc. is a biopharmaceutical company focusing on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. A highly-qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development leads the Company. NEMUS’ vision is to provide physicians and patients the medical benefits of "condition-specific" cannabinoids to alleviate symptoms associated with a continuum of diseases. OTCQB-listed, NEMUS Bioscience is headquartered in Costa Mesa, California.
NEMUS is concentrating on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds - cannabinoids - designed to alleviate an array of diseases and symptoms through selectively targeting CB1 and CB2 receptors. The Company signed a research agreement with the University of Mississippi (UM) in 2015. The research agreement is to study and conduct R&D on cannabidiol (CBD) containing formulations.
NEMUS is building a proprietary product pipeline centering on the range from extraction processes to molecular design and inventive methods of cannabinoid drug delivery to address medical needs in the multi-billion-dollar worldwide market opportunities. NEMUS, utilizing certain proprietary technology licensed from the University of Mississippi (UM), is working to develop novel ways to deliver cannabinoid-based drugs for specific indications. The Company’s goal is optimizing the clinical effects of such drugs, while limiting the potential adverse events. Its strategy will explore the use of natural and synthetic compounds, alone or in combination.
NEMUS Bioscience has completed the validation stage of testing of its cannabinoid-based therapy undergoing development for the treatment and management of glaucoma. The therapy, NB1111, is a proprietary prodrug version of tetrahydrocannabinol (THC), which has been shown to reduce intraocular pressure (IOP) in a rabbit glaucoma model. This compound has been in-licensed from NEMUS’ commercial and research partner, the University of Mississippi (UM).
Last month, NEMUS Bioscience announced that it signed a licensing agreement with the University of Mississippi (UM) for a platform of cannabinoid-based molecules (UM5070) for potential anti-infective use against bacteria, viruses, and fungi. The agreement concludes approximately one year of screening and target molecule identification studies particularly centered on therapy-resistant infectious organisms like methicillin-resistant Staphylococcus aureus (MRSA).
At the end of January, NEMUS Bioscience announced that it signed a research agreement with the University of Mississippi (UM) to further explore the analgesic and abuse-deterrent properties of NB2111, an innovative analogue of cannabidiol (CBD). The Company anticipates that these planned in vivo studies will serve to complement and expand upon early data, which showed NB2111 provided dose-dependent analgesia similar to opioids in animals exposed to noxious stimuli. Additionally, NB2111 exhibited anti-addictive activity against opioids in a validated animal model of abuse liability.
NEMUS Bioscience, Inc. (NMUS), closed Friday's trading session at $0.42, up 0.24%, on 808,526 volume with 202 trades. The average volume for the last 60 days is 88,382 and the stock's 52-week low/high is $0.30/$1.80.
Cannabics Pharmaceuticals, Inc. (CNBX)
Promotion Stock Secrets, Wealth Insider Alert, Wall Street Mover, Market Intelligence Center, StreetAuthority Daily, Wall Street Daily, TopPennyStockMovers, Stockgoodies, and Cannabis Financial Network News reported earlier on Cannabics Pharmaceuticals, Inc. (CNBX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Cannabics Pharmaceuticals, Inc.’s commitment is to the development of advanced cannabinoid-based treatments and therapies. Its main emphasis is the development of novel therapies and biotechnological tools designed to provide relief from diverse ailments and treat human malignancies. Cannabics’ vision is to create individually tailored natural therapies for cancer patients, employing advanced screening systems and personalized bioinformatics tools.
The Company formerly went by the name American Mining Corp. It changed its name to Cannabics Pharmaceuticals, Inc. in May 2014. The Company is based in Bethesda, Maryland.
Cannabics Pharmaceuticals has licensed Research and Development (R&D) based in Israel. This R&D’s devotion is to the development of palliative and personalized Anti-Cancer treatments channelling the multipurpose therapeutic values of cannabinoids to create tailored therapies for cancer patients. The Company’s integrated technology has created a successful medically standardized delivery system providing patients natural, reliable, and safe therapy.
The Company’s advanced tools include novel delivery systems, personalized medicine diagnostics, and therapies based on cannabinoid compounds. Cannabics’ principal Technology is Cannabics SR. This is a technology for a long acting oil capsule that provides a safe, effective, and reliable administration of cannabis. This Technology’s composition is solely from food grade materials.
Cannabics Pharmaceuticals has filed an exclusive provisional patent application with the US Patent & Trademark Office (USPTO) on an entirely new scheme of technology for implementation of its Slow Release technology for medical capsules. The clinical data collected and its scientific research are targeted for the development of personalized anti-cancer treatments.
Cannabics Pharmaceuticals has placed its wholly-owned subsidiary, "Grin Ultra Ltd.", and all accompanying Intellectual Property (IP) rights into its public company. Established in 2014, Grin Ultra is specifically licensed by the Israeli Health Ministry for cannabinoid research, allowing the Company significant opportunities to conduct its cutting-edge R&D.
Recently, Cannabics Pharmaceuticals announced that results from its Cancer HTS research indicates that specific ratios of Cannabinoids led to Apoptosis in MDA-MB-231 Breast Cancer cell viability. At present, the Company is developing a personalized treatment based upon screening of patients' biopsy and delivering specified cannabinoid medicine that contains anti-tumor properties. The belief is that this technology will enable oncologists and other treating physicians to provide cancer patients with a personalized anti-cancer cannabinoid based therapy.
In early January 2017, Cannabics Pharmaceuticals announced a new dosage of 5mg THC Cannabis capsule treating cancer patients suffering from Cachexia and Anorexia Syndrome. Currently, the Cannabics 5mg THC capsule is undergoing evaluation by the Company in a clinical study as a palliative treatment, conducted by the oncology department at the Rambam Medical Center in northern Israel and under strict regulations of the Ministry of Health, by whom Cannabics Pharmaceuticals has been licensed since 2014.
Cannabics Pharmaceuticals, Inc. (CNBX), closed Friday's trading session at $0.965, up 2.28%, on 384,599 volume with 398 trades. The average volume for the last 60 days is 413,286 and the stock's 52-week low/high is $0.021/$1.75.
Stealth Technologies Inc. (STTH)
The QualityStocks Daily Newsletter would like to spotlight Stealth Technologies Inc. (STTH). Today, Stealth Technologies Inc. closed trading at $0.039, off by 2.50%, on 10,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 36,334, and its 52-week low/high is $0.015/$0.05.
Founded in 1999, Stealth Technologies Inc. (STTH) is focused on developing and marketing products that deliver cost effective, independently validated solutions for large addressable international and domestic markets. The company's primary target is identity protection and personal safety.
The Stealth Card represents the company's flagship solution for identity protection. Today there are more than 1.5 billion credit and debit cards in circulation with RFID chips, making it easier than ever for identity thieves to steal sensitive information without contact. The paper-thin Stealth Card offered by Stealth Technologies protects up to 12 RFID credit cards in a wallet without any batteries or charging requirements.
StealthIdentityTheft.com is an expansion of the company's commitment to provide first-rate identity protection solutions. The proprietary system underlying this identity protection and recovery service was designed in partnership with law enforcement officials. Utilizing the most effective methods of prevention involving a two-step process, StealthIdentityTheft.com is a superior answer to the non-stop identity theft taking place every day.
The international marketplace was infiltrated by Stealth Technologies when the company launched its 911 HELP NOW™ emergency medical alert device. Providing direct access with 911 service at a touch of a button, the device is packed with powerful features including a full year of battery life from standard AAA batteries, compact ergonomic design, 2-way voice and a durable, splash resistant design.
Stealth Mobile is the latest product offering introduced to leverage the Stealth Technologies' brand and sales channels established by the other products. Similar to the Stealth Card, Stealth Mobile prevents electronic pickpocketing. The product guards NFC transmissions emitted by cell phone devices, which can include personal information, messages and financial data.
Stealth Technologies recognizes the value of the rapid sales growth generated by these technologies and has multiple patents pending to safeguard its investments. With an expanding product suite and ongoing expansion into the identity theft protection marketplace, Stealth Technologies remains committed to its focus on increased growth and profitability. Disclaimer
Stealth Technologies Inc. Company Blog
Stealth Technologies Inc. News:
Stealth Technologies Summary of 2016 Highlights
Stealth Technologies Announces 911 Help Now Generation II Product
Stealth Technologies Releases Record Sales Data
Dominovas Energy Corp. (DNRG)
The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.001, up 11.11%, on 1,896,445 volume with 12 trades. The stock’s average daily volume over the past 60 days is 14,225,282 and its 52-week low/high is $0.0009/$0.037.
Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.
At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.
In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.
Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer
Dominovas Energy Corp. Blog
Dominovas Energy Corp. News:
Dominovas Energy Enters Formal Negotiations to Open in India and Indonesia
Dominovas Energy Continues Discussions with Madagascar for Energy Projects
Dominovas Energy Secures Gas Supply for South Africa
Singlepoint, Inc. (SING)
The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0593, up 30.62%, on 37,444,055 volume with 1,404 trades. The stock’s average daily volume over the past 60 days is 4,784,473, and its 52-week low/high is $0.0055/$0.0503.
Singlepoint, Inc. (SING) provides mobile technology and marketing solutions that enable companies, nonprofits and religious organizations to conduct business transactions, accept donations, and engage in targeted communication via mobile devices. Through diversification of its own model, the company is also leveraging its core technology to expand into the mobile auctions and daily fantasy sports markets.
SING currently has two fundraising solutions. Text2Bid is an interactive way to increase auction revenues. The technology makes it easy for people to bid in auctions from any text or web-enabled phone. Donate by Text allows nonprofits to securely collect one-time or recurring donations via text. This capability creates a personal experience for the donors, and enables ongoing communication between the donor and nonprofit or event sponsor.
SING's payment solutions include point-of-sale (POS) terminals, loyalty programs, payment processing, phone services and financing. Pay by Text™ enables a business to accept payment transactions and, in essence, turns the user's mobile phone into a point-of-sale device. Operating on the same platform as mobile marketing, Pay by Text is designed to increase revenues, raise the average per-transaction amount, and create a fast, easy and hassle-free method of payment.
As part of its diversification and expansion strategy, SING recently acquired an interest in DraftFury (www.draftfury.com), a company that offers skill-based NBA, NFL and MLB daily fantasy sports (DFS) contests. DraftFury is known for its innovative offerings and originality, and is the first cash-flow-positive DFS enterprise. This transaction places SING in a multi-billion dollar industry expected to generate entry fees of $14.4 billion in 2020. Under the guidance of a leadership team well-versed in technology, engineering, marketing and raising capital, SING anticipates a strong foothold in its chosen markets. Disclaimer
Singlepoint, Inc. Company Blog
Singlepoint, Inc. News:
SinglePoint, Inc. Signs LOI to Invest $800K in Jacksam Corp., Creator of Revolutionary Cannabis Technology
Singlepoint, Inc. Builds Its Payments Footprint in the Cannabis Industry -- CFN Media
Mounting Support for Marijuana Banking Has Widespread Implications
eXp World Holdings, Inc. (EXPI)
The QualityStocks Daily Newsletter would like to spotlight eXp World Holdings, Inc. (EXPI). Today, eXp World Holdings, Inc. closed trading at $3.4999, up 0.80%, on 13,084 volume with 30 trades. The stock’s average daily volume over the past 60 days is 10,756, and its 52-week low/high is $0.70/$5.84.
eXp World Holdings, Inc. (EXPI) is the holding company for a number of businesses, most notably eXp Realty LLC, the Agent-Owned Cloud Brokerage™. eXp Realty is a full-service real estate brokerage offering 24/7 access to a suite of collaborative tools, training features and socialization channels designed to meet the unique needs of real estate brokers and agents. By creating a fully-immersive, cloud office environment for real estate professionals, eXp effectively reduces agents' overhead, increases their profits and provides greater service value to consumers.
Through eXp Realty's innovative platform, agents and brokers are afforded the opportunity to earn equity in exchange for production and contributions to company growth. Additionally, eXp features an aggressive revenue sharing program that pays agents a percentage of the gross commission income earned by fellow professionals they recruit into the company. The result is a shared ownership community featuring a synergistic and collaborative group of forward-thinking, entrepreneurial professionals. With the emergence of the internet as the most powerful property marketing and advertising medium, eXp's internet and cloud technologies have helped thousands of consumers find, buy or sell homes without the need for a brick and mortar real estate office.
Since its launch in October 2009, eXp Realty has experienced rapid growth, with brokerage service now offered in 35 U.S. states and Alberta, Canada. In February 2016, the company officially welcomed its 1,000th real estate professional into its family of agent-owners, up from just 467 agents at the end of 2014. Following this achievement, the Agent-Owned Cloud Brokerage claimed a spot among the top 50 real estate brokerages in the United States based on agent count, according to data from RISMEDIA's 2015 PowerBroker 500 Report.
Similarly, eXp Realty generated record financial results during 2015. Following the launch of two new initiatives – including an online lead generation program and a stock compensation plan – the company achieved a 71 percent year-over-year increase in net revenues, recording $22.87 million for the year. As it continues to expand its footprint across North America, eXp Realty will look to leverage its unique agent-owned business model to continue attracting driven, entrepreneurial agents and real estate industry leaders while promoting sustainable financial growth. Disclaimer
eXp World Holdings, Inc. Company Blog
eXp World Holdings, Inc. News:
eXp Realty Nearly Triples Agent Count in 2016
eXp World Holdings, Inc. Announces Appointment of Independent Director
eXp World Holdings, Inc. Retains MZ Group as its Investor Relations Advisor
The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX). Today, ChineseInvestors.com closed trading at $1.68, off by 6.93%, on 230,708 volume with 299 trades. The stock’s average daily volume over the past 60 days is 149,850 and its 52-week low/high is $0.12/$2.75.
Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.
Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.
At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.
CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.
The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.
Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.
In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer
ChineseInvestors.com Featured in New Interview with SmallCapVoice.com
ChineseInvestors.com, Inc. to Present at NobleCon13 Annual Investor Conference
ChineseInvestors.com, Inc. (CIIX) Engages NetworkNewsWire for Corporate Communications Solutions
Today's Top 3
The QualityStocks Public Company Sponsor News